Full text is available at the source.
Abstract
Phase 2 trials report unprecedented weight reductions with retatrutide (LY3437943), a novel triple agonist targeting GLP-1, GIP, and glucagon receptors.
- Retatrutide may offer a new approach to obesity treatment beyond existing therapies.
- Weight loss observed with retatrutide is comparable to that achieved through bariatric surgery.
- The treatment could provide additional benefits for metabolic conditions like NASH and cardiovascular disease.
- This drug illustrates advancements in multi-agonist peptide design, potentially changing obesity pharmacotherapy.
Simplified